Literature DB >> 31014118

Expression tendency and prognostic value of TCF21 in hepatocellular carcinoma.

Wei Lu1, Chao Yang1, Peng Du1, Jun-Li Zhang1, Jia-Cheng Zhang1.   

Abstract

BACKGROUND: Transcription factor 21 (TCF21) is identified as a tumor suppressor in a variety of human tumors. The purpose of the study was to examine its expression tendency and prognostic value in hepatocellular carcinoma (HCC).
METHODS: Relative expression of TCF21 mRNA in tissue samples from HCC patients and healthy volunteers were detected through quantitative real-time polymerase chain reaction (qRT-PCR) while its protein level was examined via immunohistochemistry analysis. Chi-square test was adopted to assess the association of TCF21 expression with the clinicopathological characteristic of the patients. Then Kaplan-Meier analysis was employed to analyze the function of TCF21 expression on overall survival among HCC patients.
RESULTS: Both the mRNA and protein levels of TCF21 were significantly reduced in HCC tissue samples compared with healthy controls (p < .05). Also, its expression was obviously affected by the classification of tissue pathology, metastasis, T stage, N stage and pathological grading. According to Kaplan-Meier analysis, patients with higher expression of TCF21 experienced dramatically longer overall survival time than those with lower expression (log rank test, p < .001).
CONCLUSIONS: TCF21 expression was decreased in HCC patients and it could act as a prognostic marker.

Entities:  

Keywords:  TCF21; hepatocellular carcinoma; prognosis; qRT-PCR

Mesh:

Substances:

Year:  2019        PMID: 31014118     DOI: 10.1080/21691401.2019.1601102

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  3 in total

1.  The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma.

Authors:  Yubo Ding; Jingwei Yao; Meiling Wen; Xiong Liu; Jialu Huang; Minghui Zhang; Yu Zhang; Yufan Lv; Zhuoyi Xie; JianHong Zuo
Journal:  PeerJ       Date:  2022-05-17       Impact factor: 3.061

2.  CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.

Authors:  Zhao-Ru Dong; Ai-Wu Ke; Tao Li; Jia-Bing Cai; Ya-Fei Yang; Wei Zhou; Guo-Ming Shi; Jia Fan
Journal:  Mol Cancer       Date:  2021-05-13       Impact factor: 27.401

Review 3.  Role of the bHLH transcription factor TCF21 in development and tumorigenesis.

Authors:  C F P Lotfi; B S Passaia; J L Kremer
Journal:  Braz J Med Biol Res       Date:  2021-03-15       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.